O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, present in approximately 45% of IDH-wildtype glioblastomas and 50–70% of IDH-mutant gliomas, emerged as the key predictive biomarker for treatment response [7,8,9,10,11,12]. Here, IDH1 is linked to central nervous system cancer.